Sign In
Buy VRNA
$106.91
+0 (+0%)
At Close: Jan 06, 2026
Verona Pharma plc (VRNA) Q4 2024 Earnings Call Transcript
02:31pm, Thursday, 27'th Feb 2025
Verona Pharma plc (NASDAQ:VRNA ) Q4 2024 Earnings Conference Call February 27, 2024 9:00 AM ET Company Participants David Zaccardelli - President and CEO Mark Hahn - CFO Christopher Martin - CCO Confe
Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
06:00am, Thursday, 27'th Feb 2025
Ohtuvayre TM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024
Verona Pharma Announces March 2025 Investor Conference Participation
06:00am, Tuesday, 18'th Feb 2025
LONDON and RALEIGH, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview
Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update
06:00am, Thursday, 13'th Feb 2025
LONDON and RALEIGH, N.C., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the four
What Makes Verona Pharma (VRNA) a Good Fit for 'Trend Investing'
09:51am, Wednesday, 12'th Feb 2025
If you are looking for stocks that are well positioned to maintain their recent uptrend, Verona Pharma (VRNA) could be a great choice. It is one of the several stocks that passed through our "Recent P
Here's Why 'Trend' Investors Would Love Betting on Verona Pharma (VRNA)
09:56am, Monday, 27'th Jan 2025
Verona Pharma (VRNA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through
Wall Street Analysts See a 30.65% Upside in Verona Pharma (VRNA): Can the Stock Really Move This High?
10:56am, Tuesday, 14'th Jan 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 30.7% in Verona Pharma (VRNA). While the effectiveness of this highly sought-after metric is questionable, the
Verona Pharma (VRNA) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Friday, 10'th Jan 2025
Verona Pharma (VRNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Verona Pharma (VRNA) is on the Move, Here's Why the Trend Could be Sustainable
10:02am, Friday, 10'th Jan 2025
If you are looking for stocks that are well positioned to maintain their recent uptrend, Verona Pharma (VRNA) could be a great choice. It is one of the several stocks that passed through our "Recent P
Verona Pharma's Ohtuvayre Defies Expectations In Q4, But Stock Alpha May Now Be Limited
01:45pm, Wednesday, 08'th Jan 2025
Verona Pharma's Ohtuvayre, a novel COPD treatment, achieved $36 million in Q4 sales, indicating strong market interest and unmet need for new therapies. Despite aggressive pricing, Ohtuvayre's broad l
Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights
06:00am, Tuesday, 07'th Jan 2025
Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectively
Verona Pharma Announces December 2024 Investor Conference Participation
02:00am, Tuesday, 19'th Nov 2024
LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview
Caligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value
08:23am, Saturday, 09'th Nov 2024
Verona Pharma has seen its share price skyrocket in anticipation of the commercial launch of its COPD treatment.
Verona Pharma to Present at Jefferies London Healthcare Conference
02:00am, Tuesday, 05'th Nov 2024
LONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview
Verona Pharma plc (VRNA) Q3 2024 Earnings Call Transcript
11:47am, Monday, 04'th Nov 2024
Verona Pharma plc (NASDAQ:VRNA ) Q3 2024 Earnings Conference Call November 4, 2024 9:00 AM ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial
